ReviewHuman vaccines2010
New insights for development of a safe and protective RSV vaccine.
Review in Human vaccines, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.Virologica Sinica · 2015Pooled it
- Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development.Pathogens (Basel, Switzerland) · 2025Review
- Article
- In silico virtual screening of lead compounds for major antigenic sites in respiratory syncytial virus fusion protein.Emergent materials · 2022Article
- Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections.Clinical & translational immunology · 2021Review
- Evaluation of Alpha-Ketoglutarate Supplementation on the Improvement of Intestinal Antioxidant Capacity and Immune Response in Songpu Mirror Carp (Frontiers in immunology · 2021Article
- Vaccine containing G protein fragment and recombinant baculovirus expressing M2 protein induces protective immunity to respiratory syncytial virus.Clinical and experimental vaccine research · 2019Article
- Unveiling Integrated Functional Pathways Leading to Enhanced Respiratory Disease Associated With Inactivated Respiratory Syncytial Viral Vaccine.Frontiers in immunology · 2019Article
- Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.Viral immunology · 2018Review
- Article
- Selective evolution of Toll-like receptors 3, 7, 8, and 9 in bats.Immunogenetics · 2017Article
- Article
- A Minimum Epitope Overlap between Infections Strongly Narrows the Emerging T Cell Repertoire.Cell reports · 2016Article
- Novel HLA-A2-restricted human metapneumovirus epitopes reduce viral titers in mice and are recognized by human T cells.Vaccine · 2016Article
- Proteomic contributions to our understanding of vaccine and immune responses.Proteomics. Clinical applications · 2015Review
- Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection.Journal of virology · 2015Article
- Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract.PloS one · 2015Article
- Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination.Human vaccines & immunotherapeutics · 2015Article
- Optimization of potent and selective quinazolinediones: inhibitors of respiratory syncytial virus that block RNA-dependent RNA-polymerase complex activity.Journal of medicinal chemistry · 2014Article
- Agents that increase AAM differentiation blunt RSV-mediated lung pathology.Journal of leukocyte biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Respiratory Syncytial Virus (RSV) is the leading cause of pneumonia and bronchiolitis in infants and children <1 year old, resulting in significant morbidity and mortality worldwide. There is currently no RSV vaccine. In the 1960s, a formalin-inactivated RSV (FI-RSV) vaccine trial led to exacerbated disease upon natural infection of vaccinees, including two deaths. The causes involved in the disastrous results of these vaccine trials are still unclear but they remain the engine for searching new avenues to develop a safe vaccine that can provide long-term protection against this important pathogen. This article reviews some of the early history of RSV vaccine development,as well as more recent information on the interaction between RSV and the host innate and adaptive immune responses. A safe and efficacious vaccine for RSV will require "re-education" of the host immune response against RSV to prevent vaccine-enhanced or severe RSV disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.